Folate-decorated Maleilated Pullulan–doxorubicin Conjugate for Active Tumor-Targeted Drug Delivery

Haitao Zhang,Fei Li,Jun Yi,Chunhu Gu,Li Fan,Youbei Qiao,Yangchun Tao,Chong Cheng,Hong Wu
DOI: https://doi.org/10.1016/j.ejps.2011.02.006
IF: 5.112
2011-01-01
European Journal of Pharmaceutical Sciences
Abstract:A novel folate-decorated maleilated pullulan–doxorubicin conjugate (abbreviated as FA–MP–DOX) for active tumor targeting was set up. The structure of this conjugate was confirmed by 1H NMR analysis. Furthermore, the conjugation efficiency, drug release property and stability of the conjugate were determined. The cellular uptake and cytotoxicity were assessed by using ovarian carcinoma A2780 cells as in vitro cell model. In vitro DOX release from FA–MP–DOX conjugate occurred at a faster rate at acidic pH compared to neutral pH (7.4). After 30h of incubation at pH 2.5, 5.0 and 7.4 the released free DOX was about 68.71%, 50.08% and 26%, respectively. Based on the IC50 values, the conjugate was found more effective with ovarian carcinoma A2780 cells than the parent drug after 48h culture. These results suggested that FA–MP–DOX conjugate could be a promising doxorubicin carrier for its targeted and intracellular delivery.
What problem does this paper attempt to address?